-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 26, July 21, 2021 China Medical and Health Industry Symbiosis Conference was held in Kunming, China
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
"2020 China Top 100 Chinese Medicine Companies Ranking" announced, Yiling Pharmaceutical ranked seventh
In recent years, Yiling Pharmaceutical has entered the fast lane of development.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
Schematic diagram ofYiling Pharmaceutical's 2016-2020 operating income growth
Under the leadership of the series of major innovationsin TCM collateral disease theory, Yiling Pharmaceutical has won the National Science and Technology Award six times
.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
In 2020, Tongxinluo, Shensongyangxin Capsules and Qiliqiangxin Capsules, the three major cardio-cerebrovascular products of Yiling Pharmaceutical, will achieve a combined sales revenue of 3.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
Join forces on a new journey and show new deeds
.
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
.
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
Medical Network, July 26, July 21, 2021 China Medical and Health Industry Symbiosis Conference was held in Kunming, China
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
"2020 China Top 100 Chinese Medicine Companies Ranking" announced, Yiling Pharmaceutical ranked seventh
In recent years, Yiling Pharmaceutical has entered the fast lane of development.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
Schematic diagram of Yiling Pharmaceutical's 2016-2020 operating income growth
Under the leadership of the series of major innovations in TCM collateral disease theory, Yiling Pharmaceutical has won the National Science and Technology Award six times
.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
In 2020, Tongxinluo, Shensongyangxin Capsules and Qiliqiangxin Capsules, the three major cardio-cerebrovascular products of Yiling Pharmaceutical, will achieve a combined sales revenue of 3.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
Join forces on a new journey and show new deeds
.
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
.
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
Medical Network, July 26, July 21, 2021 China Medical and Health Industry Symbiosis Conference was held in Kunming, China
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
.
At the meeting, the "2020 China Pharmaceutical Industry Top 100 Series List" was released, and Yiling Pharmaceutical was once again ranked as the TOP10 Chinese traditional Chinese medicine company, ranking seventh, and the ranking rose by three places
.
"2020 China Top 100 Chinese Medicine Companies Ranking" announced, Yiling Pharmaceutical ranked seventh
Enterprise business enterprise In recent years, Yiling Pharmaceutical has entered the fast lane of development.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
In 2020, Yiling Pharmaceutical's operating income will increase by 51%.
In the first quarter of this year, its revenue will increase by more than 50% year-on-year.
The five-year compound growth rate has reached 23%, showing good development.
Situation
.
Schematic diagram of Yiling Pharmaceutical's 2016-2020 operating income growth
Schematic diagram of Yiling Pharmaceutical's 2016-2020 operating income growthUnder the leadership of the series of major innovations in TCM collateral disease theory, Yiling Pharmaceutical has won the National Science and Technology Award six times
.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
TCM Chinese medicine TCM drugs drugs drugs.
Especially in January 2020, the project "Construction of TCM Vein Theory and Its Guidance for Prevention and Treatment of Microvascular Diseases" won the first prize of the 2019 National Science and Technology Progress Award
.
Currently, there are Yiling Pharmaceutical patent medicines kinds of more than 10, of which 8 included in the national medical insurance catalog, five kinds of pharmaceuticals for the country groups, to form a more extensive product group
.
In 2020, Tongxinluo, Shensongyangxin Capsules and Qiliqiangxin Capsules, the three major cardio-cerebrovascular products of Yiling Pharmaceutical, will achieve a combined sales revenue of 3.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
447 billion yuan.
After overcoming the impact of the epidemic and other unfavorable factors, it will achieve 11.
31 against the trend.
% Growth, the company's first prize of National Science and Technology Progress Award, has shown its effect on improving the market influence of the company's cardio-cerebral vascular products
.
With the continuous improvement of Yiling Pharmaceutical's technological innovation brand and the change and refinement of the marketing system, the three major cardiovascular products are expected to achieve accelerated growth
.
In addition, Lianhua Qingwen Capsule, which played an important role in the prevention and control of the epidemic, increased by 149.
89% year-on-year in 2020
.
In terms of overseas markets, Lianhua Qingwen has completed registration in more than 20 countries and regions including Canada, Russia, Indonesia, and Singapore, and is actively deploying international registration in more than 40 countries and regions
.
Join forces on a new journey and show new deeds
.
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
Medicine Medicine Medicine Chinese Medicine Chinese Medicine Chinese Medicine .
It is reported that in the future, Yiling Pharmaceuticals will continue to utilize the unique advantages of traditional Chinese medicine in disease prevention and treatment, promote the modernization and industrialization of traditional Chinese medicine , and create a new development pattern of mutual promotion of domestic and international double cycles
.
